STO · BRAIN.ST
BrainCool AB (publ)
SEK 1.03-SEK 0.04 (-3.37%)
BrainCool AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 10.26% below the high.
Loading market information…
STO · QLINEA.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:32 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Q-linea AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 61.74% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Q-linea AB (publ)’s next earnings report is currently expected on Oct 30, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Q-linea AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| SEK 158.00K-94.73% vs estimate |
| Q3 2024 | Nov 5, 2024 | -SEK 0.36+10.0% vs estimate | SEK 569.00K-92.89% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 1.03-SEK 0.04 (-3.37%)
BrainCool AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 10.26% below the high.
SEK 8.34-SEK 0.08 (-0.95%)
Integrum AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 30.15% below the high.
SEK 4.79+SEK 0.34 (+7.64%)
SenzaGen AB’s quoted price sits in the lower half of its reported 52-week range, 29.97% below the high.
SEK 0.52+SEK 0.01 (+1.37%)
Klaria Pharma Holding AB (publ.)’s quoted price sits in the lower half of its reported 52-week range, 60.98% below the high.
SEK 0.28-SEK 0.01 (-3.81%)
iZafe Group AB’s quoted price sits in the lower half of its reported 52-week range, 65.25% below the high.
SEK 0.38+SEK 0.00 (+1.08%)
Alzinova AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 81.86% below the high.
SEK 0.44+SEK 0.01 (+1.86%)
Nosa Plugs AB’s quoted price sits in the lower half of its reported 52-week range, 40.33% below the high.
SEK 0.40-SEK 0.01 (-2.69%)
AcuCort AB’s quoted price sits in the lower half of its reported 52-week range, 58.11% below the high.
